Home・Aandelen Lijst・Alkermes PLC

Alkermes PLC

Open

SectorGezondheidszorg

49.33 -1.54

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

49.05

Max

50.66

Belangrijke statistieken
By Trading Economics
Inkomsten	-116M -66M
Verkoop	8.4M 393M
K/W Sectorgemiddelde	58.589 64.641
EPS	0.38
Winstmarge	-16.92
Werknemers	2,050
EBITDA	-98M -22M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+16.01% upside

Dividenden
By Acuity
Volgende Winsten	27 okt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.1B 8.8B
Vorige openingsprijs	50.87
Vorige sluitingsprijs	49.33

Nieuwssentiment

By Acuity

10%

90%

5 / 340 Rangschikking in Healthcare

Alkermes PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 20:02 UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

31 jul 2026, 19:36 UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

30 jul 2026, 19:58 UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

29 jul 2026, 20:03 UTC

News

Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

28 jul 2026, 20:02 UTC

News

Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

24 jul 2026, 19:46 UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

22 jul 2026, 19:36 UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

21 jul 2026, 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

20 jul 2026, 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Peer Vergelijking

Prijswijziging

Alkermes PLC Prognose

Koersdoel

By TipRanks

16.01% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 57.46 USD 16.01%

Hoogste 65 USD

Laagste 38 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Alkermes PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

Buy

Hold

Sell

Gebaseerd op 13 analisten die aandelenratings hebben gegeven aan Alkermes PLC - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

5 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.